<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928785</url>
  </required_header>
  <id_info>
    <org_study_id>RPV02C</org_study_id>
    <nct_id>NCT00928785</nct_id>
  </id_info>
  <brief_title>Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults</brief_title>
  <official_title>A Randomised, Comparative, Multicentre Clinical Trial of the Immunogenicity and Safety of Tdap-IPV Vaccine and a Tetanus Monovalent Vaccine in Healthy Adults 18 Years of Age and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that a combined adult Tdap-IPV vaccine (REPEVAX®)&#xD;
      will provide similar rapid antibody responses against tetanus toxoid as a tetanus toxoid&#xD;
      vaccine alone in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-tetanus seroprotection rate (defined as the percentage of subjects with anti-tetanus antibody titre (ELISA) ≥ 0.1 IU/mL)</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titre (GMT) for tetanus antibodies in both groups</measure>
    <time_frame>Day 0, Day 1 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The anti-tetanus seroprotection rate (antibody titre ≥ 0.1 IU/mL in ELISA)</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with immediate reactions, solicited injection-site reactions, systemic reactions and unsolicited adverse events</measure>
    <time_frame>D0 to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with serious adverse events</measure>
    <time_frame>D0 to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>REPEVAX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Monovalent tetanus vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REPEVAX</intervention_name>
    <description>1 dose of 0.5 mL at Day 0</description>
    <arm_group_label>REPEVAX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Tetanus vaccine</intervention_name>
    <description>1 dose of 0.5 mL at Day 0</description>
    <arm_group_label>Monovalent tetanus vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged ≥18 years&#xD;
&#xD;
          -  Last booster with a T-containing vaccine received 5 to 10 years prior to the&#xD;
             administration of the study vaccine (documented by written evidence)&#xD;
&#xD;
          -  Subject with vaccination history of a primary immunisation with a tetanus, diphtheria&#xD;
             and poliomyelitis containing vaccine as recommended in the local vaccination calendar&#xD;
&#xD;
          -  Negative urine pregnancy test for female subjects of child-bearing potential. A female&#xD;
             subject who is of reproductive potential must agree to remain abstinent or use (or&#xD;
             have her partner use) acceptable methods of birth control during the study period&#xD;
&#xD;
          -  Subject having signed the informed consent form prior to participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute severe illness or fever (&gt;=38.0°C) within the last 3 days&#xD;
&#xD;
          -  Hypersensitivity or known allergy to one of the components of one of the study&#xD;
             vaccines (including formaldehyde, streptomycin, neomycin, polymyxin B, or&#xD;
             glutaraldehyde)&#xD;
&#xD;
          -  Anaphylactic or other allergic reactions to a previous dose of a vaccine containing&#xD;
             diphtheria or tetanus toxoids or poliomyelitis viruses or pertussis (acellular or&#xD;
             whole cell)&#xD;
&#xD;
          -  Guillain Barré syndrome or neuropathy of brachial plexus following a previous&#xD;
             vaccination with a tetanus toxoid containing vaccine&#xD;
&#xD;
          -  Known encephalopathy after receipt of a pertussis vaccine or neurological disorders&#xD;
             after an injection with the same antigens&#xD;
&#xD;
          -  Progressive or unstable neurological disorder, uncontrolled seizures or progressive&#xD;
             encephalopathy not stabilized&#xD;
&#xD;
          -  Known malignant disease, note:&#xD;
&#xD;
               -  subjects with prostate or breast cancer who are not on chemotherapeutic drugs&#xD;
                  (other than hormone blocking drugs),&#xD;
&#xD;
               -  subjects with skin cancer who are not receiving radiation therapy or&#xD;
                  chemotherapy, and&#xD;
&#xD;
               -  subjects with a history of other malignancies who have been disease-free for at&#xD;
                  least 5 years will be eligible for enrollment&#xD;
&#xD;
          -  Immunosuppressive therapy:&#xD;
&#xD;
               -  High dose (≥ 20 mg/day prednisone equivalent) systemic (≥ 14 days) corticosteroid&#xD;
                  treatment daily or on alternate day within the last 28 days (inhaled&#xD;
                  corticosteroids allowed)&#xD;
&#xD;
               -  Chemotherapeutic agents used to treat cancer or other conditions&#xD;
&#xD;
               -  Treatments associated with organ or bone marrow transplantation&#xD;
&#xD;
          -  Immune dysfunction caused by a medical condition, or any other cause (e.g., congenital&#xD;
             immunodeficiency, human immunodeficiency virus (HIV) infection, organ or bone marrow&#xD;
             transplantation, leukemia, lymphoma, Hodgkin's disease, multiple myeloma or&#xD;
             generalized malignancy)&#xD;
&#xD;
          -  Known severe thrombocytopenia or coagulation disorder contraindicating an&#xD;
             intramuscular injection&#xD;
&#xD;
          -  Administration of blood products including immunoglobulins within the last 90 days or&#xD;
             planned before Visit 3&#xD;
&#xD;
          -  Recent administration of a live vaccine (≤28 days) or an inactivated vaccine (≤14&#xD;
             days) or vaccination planned before Visit 3&#xD;
&#xD;
          -  For female subjects, pregnancy (positive pregnancy test before first blood sample) or&#xD;
             breast-feeding through Visit 3&#xD;
&#xD;
          -  Planned participation in another clinical study during the present study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Gabriel Montpied - CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital St Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Cochin - Saint-Vincent de Paul</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heilbronn</city>
        <zip>74072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Künzig</city>
        <zip>94550</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nettersheim</city>
        <zip>53947</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Offenbach am Main</city>
        <zip>63071</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reichenbach im Vogtland</city>
        <zip>8468</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>June 25, 2009</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2009</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tetanus Vaccine</keyword>
  <keyword>Tdap-IPV vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetanus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

